Regentatlantic Capital LLC trimmed its position in shares of Pfizer, Inc. (NYSE:PFE) by 1.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 420,231 shares of the biopharmaceutical company’s stock after selling 8,019 shares during the quarter. Pfizer makes up about 1.3% of Regentatlantic Capital LLC’s portfolio, making the stock its 10th biggest holding. Regentatlantic Capital LLC’s holdings in Pfizer were worth $14,116,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of the company. Asset Planning Services Ltd. increased its holdings in Pfizer by 4.9% in the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares in the last quarter. D. Scott Neal Inc. increased its holdings in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares in the last quarter. Orrstown Financial Services Inc. increased its holdings in Pfizer by 23.0% in the 1st quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer in the 1st quarter worth $121,000. Finally, Cascade Investment Advisors Inc. increased its holdings in Pfizer by 89.1% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 2,200 shares in the last quarter. 69.00% of the stock is owned by hedge funds and other institutional investors.
Pfizer, Inc. (NYSE PFE) traded down 0.03% on Friday, reaching $35.96. 14,605,376 shares of the company’s stock were exchanged. The company has a market capitalization of $213.87 billion, a PE ratio of 26.31 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.12. The company has a 50 day moving average price of $33.78 and a 200-day moving average price of $33.53.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 EPS. On average, equities research analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.
In other Pfizer news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Over the last three months, insiders sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is owned by corporate insiders.
PFE has been the subject of several recent analyst reports. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. BMO Capital Markets raised shares of Pfizer from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG reissued a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $38.04.
COPYRIGHT VIOLATION WARNING: “Pfizer, Inc. (PFE) Stake Decreased by Regentatlantic Capital LLC” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://stocknewstimes.com/2017/09/23/pfizer-inc-pfe-stake-decreased-by-regentatlantic-capital-llc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.